# Dietary Supplements and Inflammation Phase-2

> **NIH NIH P20** · UNIVERSITY OF SOUTH CAROLINA AT COLUMBIA · 2022 · $1,949,670

## Abstract

Abstract:
The overall objective of the COBRE Phase-2 for Dietary Supplements and Inflammation (CDSI) at the University
of South Carolina (USC) is to continue to build on the success of Phase-1 and advance the research
infrastructure specifically in the area of dietary supplements and inflammation by promoting multi-disciplinary
research pursued by junior investigators so that they become highly competitive in obtaining NIH R01 grants and
similar type of extramural funding to pursue their research. The overall objective is to investigate how botanicals
can attenuate inflammation and be used to prevent and/or treat inflammatory diseases. The CDSI will test the
overarching hypothesis that botanicals or their constituents regulate inflammation through epigenetic regulation
of immune cell functions. In Phase-1, we have made outstanding progress in the successful transition of all of
our junior faculty into extramurally-funded investigators. Additionally, we were successful in securing NIH
Complementary and Alternative Medicine (CAM) Center (P01) for Epigenetic Regulation of Inflammation, in
which ‘graduated’ faculty are leading the projects, thereby paving the path towards sustainability of CDSI. Thus,
the CDSI will complement the CAM Research and create a unique niche at USC in inflammation research. The
main goal of COBRE Phase-2 is to establish multi-disciplinary research that will identify the epigenetic
mechanisms through which botanicals modulate inflammation so that they or their analogs can be used to
prevent and/or treat inflammatory diseases. The US population spends ~$33.9 billion/year on CAM, of which
~$20 billion is on dietary supplements. It is becoming increasingly clear that inflammation plays a critical role in
the pathogenesis of not only autoimmune diseases but also a wide range of clinical disorders including
cardiovascular diseases, neurodegenerative disorders, obesity, aging and cancer. Thus, understanding the
mode of action of botanicals or their constituents on inflammation, could lead to novel treatment modalities with
far ranging clinical implications. The CDSI goal will be accomplished through promotion of multi-disciplinary
research pursued by 4 junior faculty in the area of inflammatory diseases, through highly structured mentoring
of each by a senior faculty and a recently graduated faculty member of the COBRE Phase-1. The junior faculty
will have access to state-of-the-art research core facilities that include Flow Cytometry, Microscopy and Imaging
Core, and Bioanalytical Core, to aid epigenetic studies. The program will be evaluated by an External Advisory
Committees consisting of nationally recognized scientists. Additionally, through institutional support, 5 new
tenure-track junior faculty will be recruited and mentored at USC to bolster and advance inflammation research.
The long term objective of the CDSI would be to build a self-sustaining, nationally and internationally recognized
multi-disciplinary Center for die...

## Key facts

- **NIH application ID:** 10428524
- **Project number:** 5P20GM103641-10
- **Recipient organization:** UNIVERSITY OF SOUTH CAROLINA AT COLUMBIA
- **Principal Investigator:** Mitzi Nagarkatti
- **Activity code:** P20 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $1,949,670
- **Award type:** 5
- **Project period:** 2012-09-01 → 2025-05-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10428524

## Citation

> US National Institutes of Health, RePORTER application 10428524, Dietary Supplements and Inflammation Phase-2 (5P20GM103641-10). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10428524. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*